Cash Flow Statement
Growth Metrics

Mimedx (MDXG) Amortization - Deferred Charges (2012 - 2013)

Mimedx recorded quarterly Amortization - Deferred Charges of -$439.0 in Q4 2013, down 101.61% quarter-over-quarter from $27236.0 in Q1 2013, and up 99.96% year-over-year from -$219.54 in Q4 2012.

Mimedx's Amortization - Deferred Charges history runs 2 years deep, the most recent figure standing at -$439.0 for Q4 2013.

  • In Q4 2013, Amortization - Deferred Charges rose 99.96% year-over-year to -$439.0; the TTM figure through Sep 2014 stood at -$439.0 (up 99.96% YoY), while the FY2013 annual figure was $1.3 million, up 6540.0% from the prior year.
  • Amortization - Deferred Charges came in at -$439.0 for Q4 2013 at Mimedx, down from $27236.0 in the prior quarter.
  • In the past five years, Amortization - Deferred Charges ranged from a high of $472749.0 in Q2 2012 to a low of -$1.2 million in Q4 2012.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Amortization - Deferred Charges (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Mimedx 530.69 Mn 370.92 Mn 41.62 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2013 -439.00
Dec 31, 2013 -439.00
Mar 31, 2013 27,236.00
Mar 31, 2013 27,236.00
Dec 31, 2012 -1.20 Mn
Dec 31, 2012 -1.20 Mn
Sep 30, 2012 439,064.00
Sep 30, 2012 439,064.00
Jun 30, 2012 472,749.00
Jun 30, 2012 472,749.00
Mar 31, 2012 310,477.00
Mar 31, 2012 310,477.00